Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ischemic Heart Disease
  Free Subscription

Articles published in
J Clin Endocrinol Metab
    January 2026

  1. Correction to: "Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome".
    J Clin Endocrinol Metab. 2026;111:e646.
    >> Share

    November 2025
  2. MAUVAIS-JARVIS F
    Testosterone and Cardiovascular Disease: The Enduring Myth.
    J Clin Endocrinol Metab. 2025 Nov 18:dgaf629. doi: 10.1210.
    >> Share

  3. MUNRO V, Law J, Matheson K, Imran SA, et al
    Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events.
    J Clin Endocrinol Metab. 2025 Nov 18:dgaf631. doi: 10.1210.
    >> Share

  4. PEPE J, Minisola S, Ettorre E, Desideri G, et al
    Cardiovascular Involvement In Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2025 Nov 14:dgaf625. doi: 10.1210.
    >> Share

  5. YEAP BB, Anawalt BD
    Endogenous testosterone, testosterone treatment, and cardiovascular health outcomes in men.
    J Clin Endocrinol Metab. 2025 Nov 12:dgaf622. doi: 10.1210.
    >> Share

    September 2025
  6. MEHRI HAJMIR M, Sayoldin B, Rahnavard A, Barberio MD, et al
    Plasma branched-chain amino acid and cardiovascular disease risk factors: a longitudinal analysis of a lifestyle trial.
    J Clin Endocrinol Metab. 2025 Sep 16:dgaf509. doi: 10.1210.
    >> Share

    August 2025
  7. BJORNSDOTTIR S, Mannstadt M, Clarke B, Spelman T, et al
    Response to Letter to the Editor From Hasebe and Su: "Higher risk of cardiovascular diseases in patients with chronic hypoparathyroidism in Sweden".
    J Clin Endocrinol Metab. 2025 Aug 25:dgaf475. doi: 10.1210.
    >> Share

  8. HASEBE M, Su CY
    Letter to the Editor from Hasebe and Su: "Increased Risk of Cardiovascular Diseases in Patients With Chronic Hypoparathyroidism in Sweden".
    J Clin Endocrinol Metab. 2025 Aug 25:dgaf474. doi: 10.1210.
    >> Share

    July 2025
  9. LONG X
    Letter to the Editor from Long: "Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom Population (ACEL-UK): Cohort Study".
    J Clin Endocrinol Metab. 2025 Jul 21:dgaf419. doi: 10.1210.
    >> Share

    June 2025
  10. XU H, Lu Y
    Letter to the editor from Xu and Lu: "Predictors of Cardiovascular Disease in Individuals With Dysbetalipoproteinemia: A Prospective Study in the UK Biobank".
    J Clin Endocrinol Metab. 2025 Jun 26:dgaf379. doi: 10.1210.
    >> Share

    May 2025
  11. LU X, Zhu X, Li G, Wu L, et al
    Habitual Coffee, Tea, and Caffeine Consumption, Circulating Metabolites, and the Risk of Cardiometabolic Multimorbidity.
    J Clin Endocrinol Metab. 2025;110:e1845-e1855.
    >> Share

  12. POHLMAN N, Patel PN, Essien UR, Tang JJ, et al
    Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.
    J Clin Endocrinol Metab. 2025 May 19:dgaf295. doi: 10.1210.
    >> Share

    April 2025
  13. BJORNSDOTTIR S, Mannstadt M, Clarke B, Spelman T, et al
    Increased risk of cardiovascular diseases in patients with chronic hypoparathyroidism in Sweden.
    J Clin Endocrinol Metab. 2025 Apr 28:dgaf257. doi: 10.1210.
    >> Share

  14. HOLLEY M, Razvi S, Maxwell I, Dew R, et al
    Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom population (ACEL-UK): Cohort Study.
    J Clin Endocrinol Metab. 2025 Apr 3:dgaf208. doi: 10.1210.
    >> Share

  15. TELES BSBS, Ramalho SHR, Bittencourt MS, Bensenor IM, et al
    Plasma levels of small HDL particles are associated with coronary atherosclerosis progression in adults with diabetes.
    J Clin Endocrinol Metab. 2025 Apr 3:dgaf215. doi: 10.1210.
    >> Share

    March 2025
  16. BENE-ALHASAN Y, Shitole SG, Buzkova P, Hirsch CH, et al
    Non-Esterified Fatty Acid Profiles and Cause-Specific Mortality: The Cardiovascular Health Study.
    J Clin Endocrinol Metab. 2025 Mar 24:dgaf182. doi: 10.1210.
    >> Share

  17. MITA T, Osonoi Y, Someya Y, Osonoi T, et al
    Relationship of carbohydrate intake proportion to cardiovascular events in Japanese people with type 2 diabetes mellitus.
    J Clin Endocrinol Metab. 2025 Mar 21:dgaf179. doi: 10.1210.
    >> Share

  18. SONAWALLA A, Chasman DI, Chan YM
    Age at Menarche and Coronary Artery Disease Risk: Divergent Associations with Different Sources of Variation.
    J Clin Endocrinol Metab. 2025 Mar 10:dgaf141. doi: 10.1210.
    >> Share

  19. NISHIO Y
    Does Insulin Work as Good One or Bad One for the Cardiovascular Tissues?
    J Clin Endocrinol Metab. 2025 Mar 7:dgaf051. doi: 10.1210.
    >> Share

    February 2025
  20. HSIAO YY, Chen YY, Kuo MJ, Chien YS, et al
    SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study.
    J Clin Endocrinol Metab. 2025 Feb 25:dgae861. doi: 10.1210.
    >> Share


  21. Correction to: "Associations Between Subclinical Thyroid Dysfunction and Cardiovascular Risk Factors According to Age and Sex".
    J Clin Endocrinol Metab. 2025 Feb 11:dgaf061. doi: 10.1210.
    >> Share

  22. JIANG L, Zhou L, Liu J, Wang Y, et al
    Sex Differences in the Association Between Thyroid Hormone Sensitivity and Cardiovascular-Kidney-Metabolic Syndrome.
    J Clin Endocrinol Metab. 2025 Feb 4:dgaf059. doi: 10.1210.
    >> Share

    January 2025
  23. CHOE HJ, Choi YM, Ha Y, Kim J, et al
    The Role of the Parametric Thyroid Feedback Quantile Index in Cardiovascular Risk Evaluation Among Euthyroid Koreans.
    J Clin Endocrinol Metab. 2025 Jan 22:dgaf046. doi: 10.1210.
    >> Share

  24. AN J, Zhang S, Cheng X, Jia C, et al
    The Association between Serum Polychlorinated Biphenyls and Incident Cardiovascular Disease among Type 2 Diabetes.
    J Clin Endocrinol Metab. 2025 Jan 15:dgaf014. doi: 10.1210.
    >> Share

  25. WANG S, Zhang Y, Balati A, Li B, et al
    Effect of Sodium-Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
    J Clin Endocrinol Metab. 2025 Jan 15:dgaf016. doi: 10.1210.
    >> Share

    December 2024

  26. Correction to: "Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study".
    J Clin Endocrinol Metab. 2024 Dec 17:dgae870. doi: 10.1210.
    >> Share

  27. BARETELLA O, Blum MR, Abolhassani N, Alwan H, et al
    Associations between subclinical thyroid dysfunction and cardiovascular risk factors according to age and sex.
    J Clin Endocrinol Metab. 2024 Dec 12:dgae860. doi: 10.1210.
    >> Share

  28. AZIZI M, Riancho J, Amar L
    Aldosterone synthase inhibitors: a potential revival for treatment of renal and cardiovascular diseases.
    J Clin Endocrinol Metab. 2024 Dec 4:dgae823. doi: 10.1210.
    >> Share

    November 2024
  29. SHI B, Liu Z, Zhang R, Tiemuerniyazi X, et al
    Subclinical hypothyroidism as an independent predictor of cardiovascular prognosis in left ventricular thrombus patients.
    J Clin Endocrinol Metab. 2024 Nov 11:dgae793. doi: 10.1210.
    >> Share

    September 2024
  30. LEBLANC E, Brooks N, Davies M, Chatterjee R, et al
    Sex-specific Cardiovascular Risk Factors and Treatment in Females with T2DM and CVD: Developments and Knowledge Gaps.
    J Clin Endocrinol Metab. 2024 Sep 23:dgae655. doi: 10.1210.
    >> Share

  31. GEORGIOPOULOS G, Athanasopoulos S, Mavraganis G, Konstantaki C, et al
    Incremental value of blood-based markers of liver fibrosis in cardiovascular risk stratification.
    J Clin Endocrinol Metab. 2024 Sep 11:dgae619. doi: 10.1210.
    >> Share

  32. PAQUETTE M, Trinder M, Guay SP, Brunham LR, et al
    Predictors of cardiovascular disease in individuals with dysbetalipoproteinemia: a prospective study in the UK Biobank.
    J Clin Endocrinol Metab. 2024 Sep 7:dgae618. doi: 10.1210.
    >> Share

    August 2024
  33. YANG C, Ji L, Han X
    Low C reactive protein-alleles in hepatocyte nuclear factor 1A are associated with an increased risk of cardiovascular disease: a Meta-analysis.
    J Clin Endocrinol Metab. 2024 Aug 30:dgae602. doi: 10.1210.
    >> Share

  34. CHENG W, Geng S, Li Y, Chen R, et al
    Sex Differences in 'Life's Essential 8' cardiovascular health and Type 2 Diabetes Mellitus Risk Across Menopause Stages.
    J Clin Endocrinol Metab. 2024 Aug 16:dgae557. doi: 10.1210.
    >> Share

  35. ABU IRSHEED G, Martyn-Nemeth P, Baron KG, Reutrakul S, et al
    Sleep disturbances in type 1 diabetes and mitigating cardiovascular risk.
    J Clin Endocrinol Metab. 2024 Aug 6:dgae539. doi: 10.1210.
    >> Share

    July 2024
  36. YOUNIS JS, Taylor HS
    Is there an Association between Endometriosis, Early Menopause, and Cardiovascular Disease?
    J Clin Endocrinol Metab. 2024 Jul 31:dgae508. doi: 10.1210.
    >> Share

  37. HEIANZA Y, Tiwari S, Wang X, Watrous JD, et al
    Gut-Microbiota-Related Metabolite Phenylacetylglutamine and Risk of Incident Coronary Heart Disease among Women.
    J Clin Endocrinol Metab. 2024 Jul 30:dgae525. doi: 10.1210.
    >> Share

  38. SONG DK, Oh J, Sung YA, Hong YS, et al
    All-cause mortality and incidence of cardiovascular diseases in lean patients with newly diagnosed type 2 diabetes.
    J Clin Endocrinol Metab. 2024 Jul 26:dgae449. doi: 10.1210.
    >> Share

  39. HENNEY AE, Gillespie CS, Lai JYM, Schofield P, et al
    Risk of type 2 diabetes, MASLD and cardiovascular disease in people living with polycystic ovary syndrome.
    J Clin Endocrinol Metab. 2024 Jul 11:dgae481. doi: 10.1210.
    >> Share

    June 2024
  40. CHAROENSRI S, Auchus RJ
    Response to Letter to the Editor From Tang and Zhang: "Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia".
    J Clin Endocrinol Metab. 2024 Jun 26:dgae402. doi: 10.1210.
    >> Share

  41. TANG C, Zhang S
    Letter to the Editor From Tang and Zhang: "Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia".
    J Clin Endocrinol Metab. 2024 Jun 26:dgae401. doi: 10.1210.
    >> Share

    May 2024
  42. STOKAR J, Szalat A
    Response to Letter to the Editor from Kawaguchi: 'Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study.
    J Clin Endocrinol Metab. 2024 May 20:dgae348. doi: 10.1210.
    >> Share

  43. KAWAGUCHI H
    Letter to the Editor from Kawaguchi: 'Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study'.
    J Clin Endocrinol Metab. 2024 May 18:dgae347. doi: 10.1210.
    >> Share

  44. FARR JN
    Cardiovascular Safety and Romosozumab - The Plot Thickens.
    J Clin Endocrinol Metab. 2024 May 8:dgae313. doi: 10.1210.
    >> Share

    April 2024
  45. KAJIKAWA M, Maruhashi T, Kishimoto S, Yamaji T, et al
    A Body Shape Index as a Simple Anthropometric Marker of Abdominal Obesity and Risk of Cardiovascular Events.
    J Clin Endocrinol Metab. 2024 Apr 25:dgae282. doi: 10.1210.
    >> Share

  46. ZHANG G, Jiang W, He F, Fu J, et al
    LDL-C and TC mediate the risk of PNPLA3 inhibition on cardiovascular diseases.
    J Clin Endocrinol Metab. 2024 Apr 18:dgae264. doi: 10.1210.
    >> Share

  47. CHE J, He N, Kuang X, Zheng C, et al
    Dietary n-3 fatty acids intake and all-cause and cardiovascular mortality in patients with pre-diabetes and diabetes.
    J Clin Endocrinol Metab. 2024 Apr 16:dgae265. doi: 10.1210.
    >> Share

  48. SONG X, Xiong L, Guo T, Chen X, et al
    Cystatin C is a predictor for long-term All-Cause and Cardiovascular Mortality in US Adults with Metabolic Syndrome.
    J Clin Endocrinol Metab. 2024 Apr 10:dgae225. doi: 10.1210.
    >> Share

    March 2024
  49. QIU Z, Lee DH, Lu Q, Li R, et al
    Associations of Regional Body Fat with Risk of Cardiovascular Disease and Mortality among Individuals with Type 2 Diabetes.
    J Clin Endocrinol Metab. 2024 Mar 26:dgae192. doi: 10.1210.
    >> Share

  50. VAN DER VALK ES, Mohseni M, Iyer AM, van den Hurk M, et al
    Long-term glucocorticoid exposure and incident cardiovascular diseases - the Lifelines cohort.
    J Clin Endocrinol Metab. 2024 Mar 19:dgae081. doi: 10.1210.
    >> Share

  51. STOKAR J, Szalat A
    Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study.
    J Clin Endocrinol Metab. 2024 Mar 14:dgae173. doi: 10.1210.
    >> Share

  52. COSTA FC, Gomes LG, de Lima TM, Bortolotto LA, et al
    Cardiovascular risk in women with nonclassical congenital adrenal hyperplasia.
    J Clin Endocrinol Metab. 2024 Mar 11:dgae155. doi: 10.1210.
    >> Share

    February 2024
  53. CHEN GC, Hukportie DN, Liu YJ, Wang HP, et al
    Microvascular Disease, Cardiovascular Health, and Risk of Coronary Heart Disease in Type 2 Diabetes: A UK Biobank Study.
    J Clin Endocrinol Metab. 2024 Feb 27:dgae100. doi: 10.1210.
    >> Share

    January 2024
  54. PARK SY, Jun JE, Jeong IK, Ahn KJ, et al
    Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes.
    J Clin Endocrinol Metab. 2024 Jan 4:dgad714. doi: 10.1210.
    >> Share

    October 2023
  55. HIRSCHBERG AL
    Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women-What Is the Evidence?
    J Clin Endocrinol Metab. 2023 Oct 27:dgad590. doi: 10.1210.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016